News & Updates
Filter by Specialty:
S-ketamine anaesthesia improves recovery following modified radical mastectomy
A prospective randomized controlled trial of breast cancer (BC) patients undergoing modified radical mastectomy (MRM) finds that S-ketamine used in place of sufentanil for general anaesthesia (GA) improves postoperative recovery.
S-ketamine anaesthesia improves recovery following modified radical mastectomy
12 Jul 2023
Palliative care for interstitial lung disease more difficult than for lung cancer
Providing palliative care (PC) for patients with interstitial lung disease (ILD) appears more challenging than for those with lung cancer (LC), according to a study. Pulmonary specialists have also cited some ILD-specific barriers in PC.
Palliative care for interstitial lung disease more difficult than for lung cancer
11 Jul 2023
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
06 Jul 2023
Lazertinib improves PFS vs gefitinib in 1L treatment of EGFR-mutated NSCLC
The third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib significantly improves progression-free survival (PFS) vs gefitinib in first-line (1L) treatment of patients with EGFR -mutated, locally advanced or metastatic non-small-cell lung cancer (NSCLC) harbouring an exon 19 deletion or exon 21 L858R mutation, results of the phase III LASER301 trial have shown.
Lazertinib improves PFS vs gefitinib in 1L treatment of EGFR-mutated NSCLC
06 Jul 2023
Dalpiciclib a 1L option for HR-positive, HER2-negative advanced breast cancer regardless of menopausal status
Adding dalpiciclib to an aromatase inhibitor (AI) significantly improves progression-free survival (PFS) vs an AI alone in first-line (1L) treatment of hormone receptor (HR)–positive, HER2-negative advanced breast cancer regardless of patients’ menopausal status, a phase III trial in 42 hospitals in China has shown.
